A better delivery system brings anti-inflammatory therapies to critical sites
Arthritis flares — the unpredictable and often sudden worsening of arthritis symptoms — can be debilitating. These episodes can make the management of inflammatory arthritis, which includes rheumatoid arthritis and psoriatic arthritis, challenging for patients and physicians.
But investigators at Harvard-affiliated Brigham and Women’s Hospital (BWH) have found that flares may also represent an important opportunity for improving treatment options.
In experiments carried out in the lab, BWH bioengineers have developed a hydrogel — a soft, flexible material that can be loaded with arthritis drugs and injected locally into an inflamed joint. Instead of delivering the drug continuously at a steady rate, the hydrogel is designed to respond to increased disease activity during flares, releasing the drug when symptoms worsen. The team’s laboratory-based findings are published this week in Nature Communications and investigators are working on next steps to bring their technology closer to the clinic.
“Arthritis represents a huge unmet clinical need,” said co-senior author Jeff Karp,a bioengineer and principal investigator at BWH and Harvard Medical School (HMS) professor of medicine. “Although new therapeutics have been developed, many have had systemic, toxic effects. We wanted to design a delivery system that could be efficient, deliver drugs locally, and release drugs in response to inflammation.”
The newly created flare-responsive hydrogel is made from triglycerol monostearate (TG-18), a compound from the Food and Drug Administration’s list of “generally recognized as safe” compounds. TG-18 is a molecule capable of self-assembling, meaning that it can form a gel-like structure comprising fibers. This structure can be easily injected as a suspension. In this study, the TG-18 hydrogel was loaded with triamcinolone acetonide (TA), used here as a model drug, but could potentially be loaded with many other kinds of anti-inflammatory compounds.
“The hydrogel is designed so that drug release is triggered by the activity of specific, arthritis-related enzymes that are increased during flares. To test the TG-18 hydrogel, we exposed the gel to several different kinds of environments mimicking conditions in arthritic joints,” said Nitin Joshi, co-first author on the work and an instructor of medicine at BWH and HMS.
When the gel was incubated in synovial fluid from a healthy human joint, drug release was minimal, but when incubated in synovial fluid from a patient with rheumatoid arthritis, the drug was readily released from the hydrogel. Importantly, the drug supply was not exhausted in one spike of synovial fluid — instead, it could be released in response to multiple spikes over time. The team also tested the hydrogel’s effects on cells from cartilage and joints, and found that it appeared to be safe.
The team further tested the clinical efficacy of the TG-18 hydrogel in a mouse model of inflammatory arthritis. They chose the K/BxN serum transfer model, in which disease severity can be precisely controlled, which allowed them to test the hydrogel in animals with different degrees of arthritis severity. They found that when arthritis was more severe, the locally injected hydrogel degraded more rapidly, corresponding to increased drug release. Swelling and severity of arthritis diminished in response to the drug-loaded hydrogel.
One of the advantages of the hydrogel is that it offers the promise of treating arthritis specifically in the joints where the disease is flaring, rather than delivering a drug throughout the body.
“Local therapy could be a viable treatment option for patients with only one or a few inflamed joints, said co-corresponding author Joerg Ermann, a rheumatologist in the BWH Division of Rheumatology, Immunology, and Allergy and HMS instructor in medicine. “Moreover, if a patient is already on a systemic drug but is experiencing a flare in a limited number of joints, we could specifically treat these joints rather than switching to systemic therapy or adding another systemic drug. Having this option would substantially increase our ability to successfully manage arthritis flares in the clinic.”
The team will continue testing the hydrogel in preclinical models to further validate it, and continue to advance toward human clinical trials. The technology has been licensed by Alivio Therapeutics, which is developing therapies to treat inflammatory disorders via targeted disease immunomodulation.
Learn more: Treating inflammatory arthritis with hydrogel
The Latest on: Inflammatory arthritis
via Google News
The Latest on: Inflammatory arthritis
- Subclinical Heart Inflammation Seen in RA on November 12, 2018 at 10:36 am
A study using 18-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) found that rheumatoid arthritis (RA) disease activity was correlated with more myocardial inflammation ... […]
- Generic arthritis drug comes up short against inflammation in heart disease on November 10, 2018 at 1:51 pm
Giving a generic anti-inflammatory drug widely used to treat rheumatoid arthritis to people who previously had a heart attack or stroke worked no better than placebo in preventing another cardiovascul... […]
- The diet that may help treat joint stiffness and pain on November 10, 2018 at 5:38 am
People with chronic illnesses often search for alternative ways to help their condition, and rheumatoid arthritis patients are no different. Some insist that following an anti-inflammatory diet can he... […]
- 34 Things You Need to Know About Arthritis on November 2, 2018 at 9:27 am
Identifying arthritis early gives you time to turn to lifestyle changes before irreversible damage is done to your knees (the most common pain point) or other joints. Up to 85 percent of osteoarthriti... […]
- Statins May Decrease C-Reactive Protein Levels in Psoriatic Arthritis on October 24, 2018 at 1:15 pm
CHICAGO — Statin therapy may lower C-reactive protein (CRP) levels in patients with psoriatic arthritis (PsA), according to a study presented at the American College of Rheumatology Annual Meeting, Oc... […]
- Alpine Immune Sciences’ Lead Program ALPN-101 Demonstrates Preclinical Activity in Inflammatory Arthritis and Neurological Inflammation on October 23, 2018 at 5:33 am
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company, presented positive results from preclinical studies of its lead program ALPN-101, a dual ICOS/CD2... […]
- Report: Omer Asik Out Indefinitely with Inflammatory Arthritis on September 23, 2018 at 12:02 am
OFFICIAL: Bulls center Omer Asik is out indefinitely with inflammatory arthritis. He has been receiving ongoing medical treatment and management, but his return to basketball activities is yet to be d... […]
- Inflammatory arthritis to keep Omer Asik out indefinitely on September 22, 2018 at 10:21 am
Asik's arthritis flared up over the summer, and that is the key to his current diagnosis. The Bulls acquired Asik last season in the Nikola Mirotic trade with the New Orleans Pelicans. He has two year... […]
- Bulls center Omer Asik out indefinitely with inflammatory arthritis on September 22, 2018 at 8:07 am
Chicago Bulls center Omer Asik is out indefinitely with inflammatory arthritis, the team announced Saturday. The 7-foot Asik has been receiving ongoing medical treatment and management, but his return ... […]
via Bing News